Moleculin Biotech Inc (MBRX)
5.08
+0.05
(+0.99%)
USD |
NASDAQ |
May 17, 16:00
5.08
0.00 (0.00%)
After-Hours: 20:00
Moleculin Biotech Cash from Financing (TTM): 4.51M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 4.51M |
December 31, 2023 | 4.651M |
September 30, 2023 | 0.186M |
June 30, 2023 | 0.179M |
March 31, 2023 | 0.118M |
December 31, 2022 | -0.023M |
September 30, 2022 | -0.023M |
June 30, 2022 | -0.036M |
March 31, 2022 | -0.024M |
December 31, 2021 | 74.72M |
September 30, 2021 | 80.21M |
June 30, 2021 | 81.99M |
March 31, 2021 | 92.01M |
December 31, 2020 | 22.55M |
September 30, 2020 | 17.06M |
Date | Value |
---|---|
June 30, 2020 | 15.36M |
March 31, 2020 | 20.62M |
December 31, 2019 | 20.85M |
September 30, 2019 | 22.62M |
June 30, 2019 | 22.56M |
March 31, 2019 | 9.351M |
December 31, 2018 | 12.04M |
September 30, 2018 | 11.67M |
June 30, 2018 | 12.75M |
March 31, 2018 | 13.01M |
December 31, 2017 | 10.06M |
September 30, 2017 | 8.678M |
June 30, 2017 | 7.595M |
March 31, 2017 | 13.58M |
December 31, 2016 | 8.865M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.036M
Minimum
Jun 2022
92.01M
Maximum
Mar 2021
24.00M
Average
16.21M
Median
Cash from Financing (TTM) Benchmarks
Merck & Co Inc | -5.57B |
Lixte Biotechnology Holdings Inc | 3.137M |
Moderna Inc | -821.00M |
NovaBay Pharmaceuticals Inc | 1.313M |
Palatin Technologies Inc | 14.71M |